HiSiaddi is an innovative foreign trade service provider driven by both technology transformation and export business. It has established a "1+2+3+4=1" service system and can supply L-selenomethionine sourced directly from multiple well-known original manufacturers. As a tech-driven foreign trade enterprise, HiSiaddi frequently proposes formulation optimization plans and application improvement suggestions for L-selenomethionine based on factory technical transformation cooperation and precise market insight. Below is a case of formulation optimization consulting services for L-selenomethionine provided by HiSiaddi.
Contact HiSiaddi customer service for more formulation optimization consulting services.
The buyer is NUTRIPHARM AB, a Nordic pharmaceutical company headquartered in Sweden. It specializes in developing and manufacturing prescription-grade dietary supplements, thyroid support medical nutrition tablets, and lactation & pregnancy trace element softgels for the Nordic market. Its products are sold in Swedish public hospital pharmacies and premium Nordic organic supermarket chains. All raw materials comply with USP, EP Pharmacopoeia and EU EFSA food safety standards. The company rejects inorganic sodium selenite and feed-grade selenium yeast, relying exclusively on high-purity biofermented L-selenomethionine as its selenium source with an annual L-selenomethionine procurement volume of 28 tons, previously sourced long-term from Swiss fine chemical manufacturers.
To cut supply chain costs and shorten lead times, the client independently selected three domestic raw material manufacturers for trial raw material procurement. After incoming inspection, the raw materials triggered mass production failures, formulation compatibility abnormalities and unqualified shelf-life stability issues on its fully automatic tableting and softgel filling lines, resulting in a finished product scrap rate exceeding 32% and suspended new product launches. Production downtime and R&D losses surpassed EUR 73,000. Lacking domestic raw material process technical support, the client entrusted HiSiaddi to deliver full-process technical support covering raw material physical and chemical optimization, formulation improvement and end production process debugging.
The client operates two core production lines: ① 0.2mg selenium thyroid support tablets (mass-produced via high-speed rotary automatic tablet presses); ② Pregnancy & infant compound selenium softgels (low-temperature emulsification filling process). Mandatory raw material benchmarks: fermented L-selenomethionine ≥99.3%, inorganic selenium impurities <0.2ppm, moisture ≤0.6%, angle of repose 27°~30°.
After feeding general mass-produced domestic L-selenomethionine raw materials, the client faced concentrated formulation compatibility, production operation and storage stability issues — the most common technical bottlenecks when general domestic raw materials are matched with premium European preparations:
General domestic raw materials feature irregular crystal particle sizes and high fine powder ratios with severe powder static electricity. Feeding is obstructed on fully automatic high-speed tablet presses, leading to single-tablet weight RSD >6.2% within the same batch, and HPLC testing showing selenium content differences exceeding 21% between individual tablets — violating EU labeling regulations for dietary supplements and preventing finished product launch.
Raw materials leave factories with 0.95% moisture and rapidly absorb moisture under the factory’s standard Nordic humidity of 48%~55%. Caking occurs within 24 hours after mixing with microcrystalline cellulose and vitamin premix excipients. Small solid crystals separate out after softgels are stored at low temperature for 30 days, disrupting the oil phase system. Accelerated shelf-life stability testing (40°C / RH75%) shows selenium content attenuation exceeding 5% within 3 months, failing to meet the EU 24-month shelf-life standard.
General mass-produced raw materials only undergo two-stage resin purification, leaving residual trace sulfur-containing byproducts. Slow oxidation occurs after co-storage with VA and VC compound excipients, resulting in yellowed tablet surfaces and sulfurous odors, violating Nordic clean label requirements for odor-free products.
The client’s wet granulation process includes short-duration hot air drying at 65°C. Conventional domestic raw materials decompose under heat, causing 11% loss of active selenium content, resulting in finished products failing to meet labeled selenium specifications and mass semi-finished product scrapping.
The three supplying factories could only guarantee national standard factory exit indicators, lacking R&D capabilities for end-product preparation formulations and downstream production process matching. They could only adjust raw material purity and failed to optimize powder physical properties and impurity structures targeted at the client’s formulation, leaving the issues unresolved.
HiSiaddi assembled a special technical team of fine chemical raw material engineers, formulation pharmacists and food stability researchers to implement solutions in three phases: upstream domestic raw material modification optimization, midstream client end-formulation fine-tuning, and downstream factory mass production parameter rectification.
HiSiaddi coordinated cooperative fermentation manufacturers to reverse-optimize crystallization, purification and drying full processes targeting the four production failures:
1. Three-stage chromatographic deep impurity removal: An additional high-precision silica gel chromatography process was added on top of conventional two-stage purification to remove trace sulfur-containing byproducts, reducing total organic impurities from 0.28% to ≤0.11% and eliminating post-formulation oxidation, yellow discoloration and unpleasant odors;
2. Gradient temperature-controlled crystallization + classified sieving: Slow segmented cooling crystallization precisely controlled grain particle sizes, paired with low-temperature air-flow classified screening to lock the finished product angle of repose at 28.2% with full passage through 100-mesh screens, eliminating powder static electricity and fundamentally improving flowability;
3. Deep low-temperature vacuum drying: Low-temperature negative-pressure drying technology was adopted to strictly control finished product moisture at 0.42%, drastically reducing hygroscopicity with moisture absorption gain <0.8% after 72 hours under RH55% environment;
4. Thermal stability enhancement: Fine-tuned pH after fermentation refining to boost raw material heat resistance, lowering selenium loss to <1.8% during short-duration 65°C drying to match the client’s wet granulation conditions. Four rounds of samples were sent to the Swedish laboratory for physical and chemical retesting, with all raw material indicators meeting the client’s customized benchmarks.
Combined with the physical and chemical properties of modified raw materials, HiSiaddi provided compliant fine-tuning recommendations within EU excipient regulatory frameworks without altering core efficacy ratios:
1. Tablet formulation improvement: 0.3% fumed silica was added as a flow aid and moisture-proof agent to the original excipient system, high-hygroscopic starch excipients were partially replaced with low-moisture microcrystalline cellulose to improve overall powder moisture resistance and mixing uniformity, reducing single-tablet selenium content RSD to below 1.5% and meeting pharmacopoeia uniformity requirements;
2. Softgel formulation optimization: Carrier vegetable oil ratios were adjusted, with small amounts of medium-chain triglycerides added to encapsulate raw materials and isolate moisture and air, resolving crystal separation and stratification during low-temperature storage. Accelerated stability testing showed selenium attenuation ≤2.2% over 6 months, meeting the 24-month shelf-life standard.
1. Tablet press workshop control: The tablet press room was dehumidified to RH38%~43%, raw materials were fully transferred in sealed silos, and cold air devices were added to tablet punches to reduce risks of raw material oxidation and moisture absorption from temperature rises during high-speed production;
2. Granulation process adjustment: Hot air drying temperature was lowered to 58°C with shortened hot air contact duration to avoid selenium decomposition loss under high temperatures;
3. Raw material storage specifications: Custom double-layer aluminum foil moisture-proof fiber drums with built-in food-grade desiccants were used for packaging, with raw materials stored at a constant 18~22°C in Swedish warehouses to prevent moisture absorption during transportation and storage.
The first batch of 6 tons of customized modified L-selenomethionine was shipped to Sweden. After feeding into trial production, the tablet scrap rate plummeted from 32% to 1.8%. Tablets showed no yellow discoloration or odors, with full passing inspection for tablet weight and selenium uniformity. Softgels passed accelerated stability testing with no crystal separation or stratification, fully complying with Swedish food and drug administration end-product filing requirements. New product production, suspended for 45 days, was successfully launched. The annual 28-ton order was delivered in 8 separate batches. Compared with the original Swiss imported raw materials, overall procurement costs decreased by 23.5%, and sea freight lead times were shortened from 68 days to 32 days.
1. NUTRIPHARM AB of Sweden terminated all procurement from Swiss manufacturers, switching 100% of its L-selenomethionine supply to domestically customized raw materials coordinated by HiSiaddi. In the following year, customized ultra-fine selenium raw material specifications for children’s liquid drops were added, with an additional annual procurement volume of 9.2 tons;
2. Drawing on technical experience from this project, HiSiaddi continued to provide formulation technical support for trace element raw materials including selenium yeast and zinc methionine, establishing itself as the client’s exclusive Chinese raw material technical service provider.
Most domestic L-selenomethionine manufacturers only focus on national standard factory exit indicators for raw materials, lacking R&D capabilities for downstream preparation formulations and end production process matching. Mass-produced raw materials are designed for general health supplement standards with limited physical property and impurity control, making direct compatibility difficult with strict formulation systems of mid-to-high-end EU medical nutrition and prescription-grade dietary supplements. Overseas high-end pharmaceutical enterprises excel in end-preparation R&D yet lack familiarity with domestic raw material production processes, leading to frequent mass production technical failures during independent raw material procurement. Moving beyond simple raw material supply foreign trade models, HiSiaddi centers its core services on two-way technical support covering raw materials and preparations: coordinating upstream manufacturers to customize modified raw materials while supporting downstream overseas clients with formulation and production process optimization, breaking technical barriers between refined domestic raw materials and premium European preparations. This solution enables foreign pharmaceutical enterprises to cut costs and resume production, while helping domestic raw material manufacturers escape homogeneous low-price competition and access high-value EU medical nutrition raw material supply chains.
Contact HiSiaddi customer service for more formulation optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
